Literature DB >> 28126725

Alterations in the Immune Cell Composition in Premalignant Breast Tissue that Precede Breast Cancer Development.

Amy C Degnim1, Tanya L Hoskin2, Muhammad Arshad3, Marlene H Frost4, Stacey J Winham2, Rushin A Brahmbhatt3, Alvaro Pena3, Jodi M Carter5, Melody L Stallings-Mann6, Linda M Murphy4,7, Erin E Miller6, Lori A Denison8, Celine M Vachon9, Keith L Knutson10, Derek C Radisky6, Daniel W Visscher5.   

Abstract

Purpose: Little is known about the role of the immune system in the earliest stages of breast carcinogenesis. We studied quantitative differences in immune cell types between breast tissues from normal donors and those from women with benign breast disease (BBD).Experimental Design: A breast tissue matched case-control study was created from donors to the Susan G. Komen for the Cure Tissue Bank (KTB) and from women diagnosed with BBD at Mayo Clinic (Rochester, MN) who either subsequently developed cancer (BBD cases) or remained cancer-free (BBD controls). Serial tissue sections underwent immunostaining and digital quantification of cell number per mm2 for CD4+ T cells, CD8+ T cells, CD20+ B cells, and CD68+ macrophages and quantification of positive pixel measure for CD11c (dendritic cells).
Results: In 94 age-matched triplets, BBD lobules showed greater densities of CD8+ T cells, CD11c+ dendritic cells, CD20+ B cells, and CD68+ macrophages compared with KTB normals. Relative to BBD controls, BBD cases had lower CD20+ cell density (P = 0.04). Nearly 42% of BBD cases had no CD20+ B cells in evaluated lobules compared with 28% of BBD controls (P = 0.02). The absence of CD20+ cells versus the presence in all lobules showed an adjusted OR of 5.7 (95% confidence interval, 1.4-23.1) for subsequent breast cancer risk.Conclusions: Elevated infiltration of both innate and adaptive immune effectors in BBD tissues suggests an immunogenic microenvironment. The reduced B-cell infiltration in women with later breast cancer suggests a role for B cells in preventing disease progression and as a possible biomarker for breast cancer risk. Clin Cancer Res; 23(14); 3945-52. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28126725     DOI: 10.1158/1078-0432.CCR-16-2026

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  15 in total

1.  Preexisting Commensal Dysbiosis Is a Host-Intrinsic Regulator of Tissue Inflammation and Tumor Cell Dissemination in Hormone Receptor-Positive Breast Cancer.

Authors:  Claire Buchta Rosean; Raegan R Bostic; Joshua C M Ferey; Tzu-Yu Feng; Francesca N Azar; Kenneth S Tung; Mikhail G Dozmorov; Ekaterina Smirnova; Paula D Bos; Melanie R Rutkowski
Journal:  Cancer Res       Date:  2019-05-07       Impact factor: 12.701

2.  Inflammation markers on benign breast biopsy are associated with risk of invasive breast cancer in African American women.

Authors:  Asra N Shaik; Katrin Kiavash; Karri Stark; Julie L Boerner; Julie J Ruterbusch; Hany Deirawan; Sudeshna Bandyopadhyay; Rouba Ali-Fehmi; Gregory Dyson; Michele L Cote
Journal:  Breast Cancer Res Treat       Date:  2020-10-28       Impact factor: 4.872

3.  Relation of Quantitative Histologic and Radiologic Breast Tissue Composition Metrics With Invasive Breast Cancer Risk.

Authors:  Mustapha Abubakar; Shaoqi Fan; Erin Aiello Bowles; Lea Widemann; Máire A Duggan; Ruth M Pfeiffer; Roni T Falk; Scott Lawrence; Kathryn Richert-Boe; Andrew G Glass; Teresa M Kimes; Jonine D Figueroa; Thomas E Rohan; Gretchen L Gierach
Journal:  JNCI Cancer Spectr       Date:  2021-02-06

4.  CD56+ immune cell infiltration and MICA are decreased in breast lobules with fibrocystic changes.

Authors:  Daniel Kerekes; Daniel W Visscher; Tanya L Hoskin; Derek C Radisky; Rushin D Brahmbhatt; Alvaro Pena; Marlene H Frost; Muhammad Arshad; Melody Stallings-Mann; Stacey J Winham; Linda Murphy; Lori Denison; Jodi M Carter; Keith L Knutson; Amy C Degnim
Journal:  Breast Cancer Res Treat       Date:  2017-11-01       Impact factor: 4.872

Review 5.  New Insights into Tumor-Infiltrating B Lymphocytes in Breast Cancer: Clinical Impacts and Regulatory Mechanisms.

Authors:  Meng Shen; Jian Wang; Xiubao Ren
Journal:  Front Immunol       Date:  2018-03-08       Impact factor: 7.561

6.  High mammographic density in women is associated with protumor inflammation.

Authors:  Cecilia W Huo; Prue Hill; Grace Chew; Paul J Neeson; Heloise Halse; Elizabeth D Williams; Michael A Henderson; Erik W Thompson; Kara L Britt
Journal:  Breast Cancer Res       Date:  2018-08-09       Impact factor: 6.466

7.  Infiltrating immune cells in benign breast disease and risk of subsequent invasive breast cancer.

Authors:  Thomas E Rohan; Rhonda Arthur; Yihong Wang; Sheila Weinmann; Mindy Ginsberg; Sherene Loi; Roberto Salgado
Journal:  Breast Cancer Res       Date:  2021-01-30       Impact factor: 6.466

Review 8.  Crosstalk between Tumor-Infiltrating Immune Cells and Cancer-Associated Fibroblasts in Tumor Growth and Immunosuppression of Breast Cancer.

Authors:  Jarupa Soongsathitanon; Pranisa Jamjuntra; Nuttavut Sumransub; Supaporn Yangngam; Marjorie De la Fuente; Glauben Landskron; Peti Thuwajit; Marcela A Hermoso; Chanitra Thuwajit
Journal:  J Immunol Res       Date:  2021-07-13       Impact factor: 4.818

Review 9.  Immune Responses and Risk of Triple-negative Breast Cancer: Implications for Higher Rates among African American Women.

Authors:  Joshua W Ogony; Derek C Radisky; Kathryn J Ruddy; Steven Goodison; Daniel P Wickland; Kathleen M Egan; Keith L Knutson; Yan W Asmann; Mark E Sherman
Journal:  Cancer Prev Res (Phila)       Date:  2020-08-04

10.  Somatic mutations in benign breast disease tissues and association with breast cancer risk.

Authors:  Stacey J Winham; Chen Wang; Ethan P Heinzen; Aditya Bhagwate; Yuanhang Liu; Samantha J McDonough; Melody L Stallings-Mann; Marlene H Frost; Robert A Vierkant; Lori A Denison; Jodi M Carter; Mark E Sherman; Derek C Radisky; Amy C Degnim; Julie M Cunningham
Journal:  BMC Med Genomics       Date:  2021-07-14       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.